248 results on '"Majewski, Ian J"'
Search Results
2. Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies
3. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
4. Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression
5. The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia
6. Uridine–cytidine kinase 2 potentiates the mutagenic influence of the antiviral β-d-N4-hydroxycytidine
7. MINTIE: identifying novel structural and splice variants in transcriptomes using RNA-seq data
8. MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML
9. Finding a suitable library size to call variants in RNA-Seq
10. A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction
11. Supplementary Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
12. Data from Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
13. Supplementary Table 1 from CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors
14. Data from CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors
15. Supplementary Figures 1-8 from CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors
16. Data from Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines
17. Supplementary Tables 2-8, 13 and 14 from Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines
18. Supplementary Information from Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines
19. Supplementary File 1 - Models and inference results from Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines
20. Data from Epigenetic Regulator Smchd1 Functions as a Tumor Suppressor
21. Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition
22. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
23. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
24. Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis
25. Jarid2 regulates hematopoietic stem cell function by acting with polycomb repressive complex 2
26. ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemia
27. Germline MBD4 deficiency causes a multi-tumor predisposition syndrome
28. Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma
29. Additional file 3 of Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies
30. Additional file 2 of Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies
31. A Mutation in the Translation Initiation Codon of Gata-1 Disrupts Megakaryocyte Maturation and Causes Thrombocytopenia
32. Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells
33. ALLSorts: a RNA-Seq classifier for B-Cell Acute Lymphoblastic Leukemia
34. Hematopoietic defects in the Ts1Cje mouse model of Down syndrome
35. Detecting copy number alterations in RNA-Seq using SuperFreq
36. The crux of Cux1 in myeloid neoplasms
37. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
38. Additional file 2 of MINTIE: identifying novel structural and splice variants in transcriptomes using RNA-seq data
39. Taming the dragon: genomic biomarkers to individualize the treatment of cancer
40. CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors
41. Life without mismatch repair
42. Additional file 1 of Finding a suitable library size to call variants in RNA-Seq
43. A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction.
44. The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism
45. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing
46. An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer
47. A regression model for estimating DNA copy number applied to capture sequencing data
48. ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity
49. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
50. CHK2 inhibition provides a strategy to suppress hematological toxicity from PARP inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.